Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 4/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30385846 | 1.00 | LPL (0.40) | LPLLIPGEGFRUCHL1CSF1R | |
| SCHEMBL30129031 | 0.88 | LPL (0.37) | LPLLIPGEGFRCSF1RTUBB1 | |
| SCHEMBL23692939 | 0.88 | LPL (0.37) | LPLLIPGEGFRCSF1RTUBB1 | |
| SCHEMBL16046869 | 0.87 | EGFR (0.39) | LPLLIPGEGFRUCHL1CSF1R | |
| SCHEMBL25209269 | 0.87 | LPL (0.36) | LPLLIPGEGFRCSF1RCA1 | |
| SCHEMBL23538053 | 0.87 | EGFR (0.39) | LPLLIPGEGFRUCHL1CSF1R | |
| SCHEMBL30129234 | 0.87 | EGFR (0.39) | LPLLIPGEGFRUCHL1CSF1R | |
| SCHEMBL29427091 | 0.86 | LPL (0.41) | LPLLIPGEGFRCSF1RCA1 | |
| SCHEMBL9948522 | 0.86 | LPL (0.41) | LPLLIPGEGFRCSF1RCA1 | |
| SCHEMBL21823670 | 0.85 | FPR2 (0.38) | LPLLIPGEGFRUCHL1TUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023118267-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023118267-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2023-06-29 | — | — | WO | disclosed |
| CN-115916784-A | Novel imidazopyrazine derivatives | 豪夫迈·罗氏有限公司 | 2023-04-04 | — | — | CN | disclosed |
| WO-2022256702-A1 | SUBSTITUTED TETRAHYDROFURAN-2-CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-12-08 | — | — | WO | disclosed |
| EP-3255042-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC (KR) | 2020-12-30 | — | — | EP | disclosed |
| US-20200190062-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC. (KR) | 2020-06-18 | — | — | US | disclosed |
| US-10611754-B2 | Heterocyclic compound and pharmaceutical composition comprising same | BEYONDBIO INC. (KR) | 2020-04-07 | — | — | US | disclosed |
| US-20190135786-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC. (KR) | 2019-05-09 | — | — | US | disclosed |
| US-10227328-B2 | Heterocyclic compound and pharmaceutical composition comprising same | BEYONDBIO INC. (KR) | 2019-03-12 | — | — | US | disclosed |
| US-20180273510-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | BEYONDBIO INC. (KR) | 2018-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135786-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CDK5, CDK1, CDK4 | LPL 3271/4885LIPG 3705/4885EGFR 875/4885 |
| US-10227328-B2 | Heterocyclic compound and pharmaceutical composition comprising same | CDK5, CDK1, CDK4 | LPL 3271/4885LIPG 3705/4885EGFR 875/4885 |
| US-20200190062-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CDK5, CDK3, CDK1 | LPL 3421/4885LIPG 3326/4885EGFR 1057/4885 |
| US-20180273510-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CDK5, CDK1, CDK4 | LPL 3271/4885LIPG 3705/4885EGFR 875/4885 |
| US-10611754-B2 | Heterocyclic compound and pharmaceutical composition comprising same | CDK5, CDK1, CDK4 | LPL 3271/4885LIPG 3705/4885EGFR 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.